The United States Drug Enforcement Administration (“DEA”) has proposed an increase in the manufacture of cannabis, cannabis extract, psilocin and psilocybin for clinical trial and research purposes. In its most recent notice, the DEA stated that its objective was to assist in the development of new federally approved therapies.
The DEA stated that it believes in supporting the regulated research of controlled substances classified under Schedule I of the Controlled Substances Act. The increase in the aggregate production quota reflects this support and will help meet the requirements for research needed for the production of new therapeutic medications.
This isn’t the first time the DEA has altered its production quotas for Schedule I substances. However, the language used now reflects a progressive attitude toward the therapeutic potential of cannabis and psychedelics, as more states legalize the substances and enact reforms.
This year, the DEA wants to produce roughly 4,400 pounds of cannabis, which is equal to 2,000 kg of cannabis. This is a 500 kg increase from its original quota for cannabis in 2021. The agency is also proposing that 500,000 grams of marijuana extract be manufactured. This amount is more than twice its initial quota for 2021.
Meeting this production goal for cannabis is bound to be easier now, given that the agency made a decision to end the monopoly on federally authorized marijuana manufacturing that the University of Mississippi had for at least five decades by authorizing additional growers for research.
The DEA has also significantly increased its production goals for psilocin and psilocybin, which are the main psychoactive components of magic mushrooms. Initially, the quota for psilocybin was set at 50 grams. This has been adjusted to 1,500 grams, which is roughly a 2,900% increase.
The original quota for psilocin was also 50 grams, with the DEA now proposing this amount be increased to 1000 grams.
Parties interested have been given 30 days to submit comment on the new production quotas for these substances after the notice is officially published.
This is great news for researchers as well as advocates, as it demonstrates a willingness from the DEA to recognize an evolving scientific field and encourage more research on the substances to be conducted, regardless of their classification under the Controlled Substances Act.
However, the higher limits may not be enough, considering the fact that these fungi and plants remain classified under the strictest drug category, despite existing research demonstrating their medical value for various conditions.
Luckily, plenty of companies such as Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) are conducting R&D focused on psychedelic substances. The positive results from their work may play a big role in changing perceptions towards psychedelics due to the medicinal value discovered in these substances.
NOTE TO INVESTORS: The latest news and updates relating to Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) available in the company’s newsroom at https://ibn.fm/TRYPF
About PsychedelicNewsWire
PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.
To receive instant SMS alerts, text “Groovy” to 888-902-4192 (U.S. Mobile Phones Only)
For more information please visit https://www.psychedelicnewswire.com
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.psychedelicnewswire.com/Disclaimer
Do you have questions or are you interested in working with PNW? Ask our Editor
PsychedelicNewsWire (PNW)
San Francisco, California
www.psychedelicnewswire.com
415.949.5050 Office
Editor@PsychedelicWire.com
PsychedelicNewsWire is part of the InvestorBrandNetwork.
